aTyr Pharma, Inc.

NASDAQ:ATYR

Biotechnology

Healthcare
$0.53 +14.23%

+$0.07 today

Market cap
$52.13M
Beta
0.54
P/E (TTM)
-0.7
EPS (TTM)
-$0.71
52W Low $0.40High $7.29

Volume 1.02M

Average 2.29M

ATYR Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

aTyr Pharma, Inc.NASDAQ: ATYR

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $394K rose 2.9% year over year, ahead of the +0.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -2.9% a year.

Context

  • Depreciation & amortization amounted to 817.4% of revenue in FY2025, up 162.0 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +2.9% holds above the trailing-twelve-month pace of +0.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$394K+0.0% QoQ
Last fiscal yearDec 2025
$1.55M+0.8% YoY
LTMMar 2026
$1.34M+0.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.9%——
1 year+0.8%——
3-year CAGR-2.9%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
1.55M USD
Year-over-year change
+0.8%
4-year CAGR
+4.5%

Depreciation & Amortization vs competitors

How ATYR compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +0.8% is the 4th highest of 8, against a peer median of -25.8%.
  • Depreciation & amortization amounts to 705.3% of revenue for ATYR, versus a peer median of 12.4%.
ATYR Competitors
Depreciation & Amortization for ATYR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DTILPrecision BioSciences, Inc.LTM Mar 2026$2.69M USD-30.3%-32.6%6.0%
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$2.28M CAD-60.7%+10.7%12.4%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$1.74M USD+3.4%—44.2%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$1.39M USD+27.4%+55.0%—
ATYRaTyr Pharma, Inc.LTM Mar 2026$1.34M USD+0.8%-2.9%705.3%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$648K USD+144.5%+52.6%—
ALXOALX Oncology Holdings Inc.LTM Mar 2026$645K USD-25.8%+27.3%—
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%——
Peer median (excluding ATYR) —-25.8%+27.3%12.4%

Competitors are the stored peer set for ATYR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue010.39M353K235K190K
Cost of Revenue1.3M1.7M001.55M
Gross Profit(1.3M)8.69M353K235K(1.36M)
Gross Margin—83.7%100.0%100.0%-717.4%
Research & Development23.26M42.81M42.29M54.37M60.22M
Selling, General & Admin10.75M12.29M12.98M13.78M17.6M
Operating Expenses32.71M55.1M55.27M68.15M76.26M
Depreciation & Amortization1.3M1.7M2.74M1.54M1.55M
EBITDA(32.47M)(43.65M)(47.66M)(62.48M)(72.57M)
EBITDA Margin—-420.3%-13500.3%-26588.1%-38192.1%
Operating Income(34.02M)(46.4M)(54.92M)(67.91M)(77.63M)
Operating Margin—-446.8%-15557.8%-28899.6%-40856.3%
Interest Income00000
Interest Expense00000
Other Income / Expenses238K1.06M4.52M3.89M3.51M
Income Before Tax(33.78M)(45.34M)(50.4M)(64.02M)(74.12M)
Pre-Tax Margin—-436.6%-14276.8%-27243.4%-39009.5%
Income Tax Expense00000
Net Income(33.77M)(45.34M)(50.39M)(64.02M)(74.12M)
Net Margin—-436.5%-14274.5%-27243.8%-39009.5%
EPS (Basic)(1.77)(1.60)(0.94)(0.86)(0.80)
EPS (Diluted)(1.77)(1.60)(0.94)(0.86)(0.80)
Weighted Avg Shares19.08M28.42M53.61M74.26M92.99M
Weighted Avg Shares (Diluted)19.08M28.42M53.61M74.26M92.99M

aTyr Pharma, Inc.

NASDAQ:ATYR

Intrinsic Alpha fair value

Locked

Current Price

$0.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.